Immune checkpoint inhibitors are monoclonal antibodies against negative immunomodulatory factor

which is used to restore body’s immune response against malignant tumors. At present

the approved drugs include cytotoxic T-lymphocyte antigen 4（ CTLA-4） inhibitor

programmed cell death 1（ PD-1） inhibitor and programmed cell death-ligand 1（ PD-L1） inhibitor

all the above drugs have typical pharmacokinetics characteristics of monoclonal antibodies

such as age

gender

race and tumor load that have no effects on the elimination of drug

except for body weight. Studies have shown that there is an exposure-response relationship in the efficacy and toxicity of CTLA-4 inhibitor and PD-1 inhibitor. Existing research results have confirmed that the clearance rates of Nivolumab and Pembrolizumab over time is related to the overall efficacy; there are few research data about the pharmacokinetics and pharmacodynamics of PD-L1 inhibitors

but it ’s clearance rate has specific variation over time

of which the Atezolizumab has high immunogenicity that may affect pharmacokinetics parameters and needs further study. This article has summarized related research on the pharmacokinetics of immune checkpoint inhibitors

explored the factors and rules that may affect its pharmacokinetics

and explored the significance of therapeutic drug monitoring for related drugs.